Evidence map›Paper›PMID 41644018›Full record

ArticleJournal of vascular surgery2026

High-quality chronic limb-threatening ischemia care requires above average performance in surgical bypass and endovascular treatment.

Douglas W Jones, Richard J Powell, Salvatore T Scali, Adam W Beck, Philip P Goodney, Jeffrey J Siracuse, Alik Farber, Gheorghe Doros, Michael B Strong, Kenneth Rosenfield and 2 more

Abstract readMulticenter StudyComparative Study
In one paragraph

Article in Journal of vascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Douglas W JonesDivision of Vascular and Endovascular Surgery, University of Massachusetts Chan Medical School, Worcester, MA. Electronic address: douglas.jones@umassmemorial.org.
Richard J PowellHeart and Vascular Center, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.
Salvatore T ScaliDivision of Vascular and Endovascular Therapy, University of Florida Health, Gainesville, FL.
Adam W BeckDivision of Vascular Surgery and Endovascular Therapy, University of Alabama at Birmingham, Birmingham, AL.
Philip P GoodneyHeart and Vascular Center, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.
Jeffrey J SiracuseDepartment of Surgery, Boston University Chobanian and Avedisian School of Medicine, Boston Medical Center, Boston, MA.
Alik FarberDepartment of Surgery, Boston University Chobanian and Avedisian School of Medicine, Boston Medical Center, Boston, MA.
Gheorghe DorosDepartment of Biostatics, Boston University School of Public Health, Boston, MA.
Michael B StrongDivision of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Kenneth RosenfieldSection of Vascular Medicine and Intervention, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Matthew T MenardDivision of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Andres SchanzerDivision of Vascular and Endovascular Surgery, University of Massachusetts Chan Medical School, Worcester, MA.

Funding

BEST-CLI Trial-DCCU01HL107407 · NHLBI · NEW ENGLAND RESEARCH INSTITUTES, INC. · PI ASSMANN, SUSAN FERA, CZIRAKY, MARK J. · 2013 to 2019
$20.0M
BEST-CLI Trial-CCC-LeadU01HL107352 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FARBER, ALIK, MENARD, MATTHEW THOMAS · 2013 to 2018
$6.1M
BEST-CLI Trial - Cost-Effectiveness of Treatments for Critical Limb IschemiaU01HL115662 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CHOUDHRY, NITEESH K · 2013 to 2018
$1.2M
NHLBI NIH HHS U01 HL107352NHLBI NIH HHS U01 HL107407NHLBI NIH HHS U01 HL115662
6 · The paper itself

Abstract

backgroundThe Best Endovascular vs Surgical Therapy in Patients with Chronic Limb-Threatening Ischemia (CLTI) (BEST-CLI) trial compared surgical bypass and endovascular treatment in patients with CLTI. Although center-level variation in vascular surgery outcomes is well-documented, its impact within BEST-CLI has not been explored. Moreover, traditional quality metrics often fail to adequately discriminate center-level performance. This study introduces cumulative, probability-based quality metrics-similar to those employed in professional sports (earned outcomes [EO] and wins above average [WAA])-to evaluate center-level performance in both surgical and endovascular treatment of CLTI. We hypothesized that high performance in both modalities conferred the best overall outcomes among centers.

methodsParticipating BEST-CLI centers were evaluated by composite major adverse limb events (MALE) or death, for all patients treated at a given site (bypass and endovascular, all BEST-CLI cohorts). WAA was calculated as a risk-adjusted, volume-sensitive measure derived from MALE/death using EO methods. Risk adjustment accounted for patient-level differences using a Cox proportional hazards model, excluding patients with incomplete data. Centers were ranked and divided into WAA quartiles from bottom (Q1) to top (Q4). Patient-level demographics and outcomes were compared across quartiles. Centers were further categorized based on WAA performance: above average (WAA >0) or below average (WAA <0) in bypass, endovascular therapy, or both.

resultsAnalyses included 1440 patients (79% of randomized patients) across 146 centers. At 2 years, unadjusted MALE/death rates varied significantly by quartile (bottom Q1, 58%; Q2, 43%; Q3, 33%; top Q4: 30%; P < .001). Centers were evenly distributed based on WAA: both modalities above average (27%), bypass above average only (27%), endovascular above average only (21%), and both below average (25%). Among top centers (Q4), 84% achieved above average outcomes in both modalities, whereas 62% of bottom centers (Q1) were below average in both. Centers excelling in only one modality constituted 16% of top centers (3% bypass above average only, 14% endovascular above average only) and 38% of bottom centers (27% bypass above average only, 11% endovascular above average only).

conclusionsMALE/death varied considerably among BEST-CLI centers, with a difference of approximately 30% seen at 2 years between the bottom and top quartiles. Top performing centers consistently achieved above-average outcomes in both bypass and endovascular treatment. Conversely, centers exceling in only one modality were less likely to be top performers. These findings suggest that optimal CLTI care demands proficiency in both bypass and endovascular treatment and highlights the need for quality metrics that better differentiate center-level performance.

Indexed as

Endovascular ProceduresIschemiaPeripheral Arterial DiseaseQuality Indicators, Health CareVascular GraftingAgedBenchmarkingChronic DiseaseClinical CompetenceFemaleHumansMaleMiddle AgedRisk AssessmentRisk FactorsTime FactorsEndovascularLower extremity bypassSurgical outcomesSurgical quality

Identifiers

PMID41644018
PMCPMC13576505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.